Tramadol and Its Influence on Platelet Function - An Ex Vivo Study.

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Tramadol is a widely used analgesic with μ-opioid receptor agonist activity.
• Tramadol also inhibits serotonin and norepinephrine reuptake, potentially affecting platelet function.
• The impact of tramadol on platelet aggregation is not well-documented, unlike selective serotonin reuptake inhibitors.

Purpose of the Study:

• To investigate the effect of tramadol on platelet function and aggregation.
• To determine if tramadol impairs platelet aggregation at therapeutic and supratherapeutic concentrations.

Main Methods:

• Laboratory study involving healthy volunteers.
• Ex vivo assessment of platelet aggregation using light transmission aggregometry.
• Platelet aggregation induced by adenosine diphosphate (ADP), ristocetin, and thrombin-receptor activating peptide (TRAP) after tramadol addition.

Main Results:

• No significant differences in platelet aggregation percentages were observed across various tramadol concentrations (0-9000 ng/mL).
• Tramadol did not impair platelet function when induced by ADP, ristocetin, or TRAP.
• Seven healthy volunteers were included in the final analysis.

Conclusions:

• Tramadol does not significantly impair platelet function in healthy individuals at tested concentrations.
• These findings support the general safety profile of tramadol concerning platelet aggregation.
• Further research with larger cohorts is needed to confirm results and explore interindividual variability.